Navigation Links
Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
Date:9/19/2011

ncer patients have HER-2 levels high enough to be eligible for Herceptin.

A controlled, randomized, and single-blinded Phase II clinical study of AE37 in HER-2 expressing breast cancer patients is currently underway to establish clinical efficacy.  The study endpoint is a reduction in cancer relapse after two years compared to patients not receiving AE37.  There are currently over 200 patients enrolled in the study with either node positive or high-risk node-negative breast cancer.  While positive preliminary results suggested that statistically definitive results could be obtained in 2012, the company opted to enroll an additional 100 patients in early 2011 to ensure sufficient patient numbers.  In particular, these additional patients are required to have low HER-2 expression levels such that they are not eligible for trastuzumab.  It is anticipated that a planned Phase 3 trial will be conducted in this specific patient population.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and oth
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Generex Provides Update on Spinout of Antigen Express
2. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
3. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
4. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
5. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
6. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
7. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
8. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
9. Medicago succesfully expresses VLP antigen for A H1N1 strain
10. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
11. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Investor-Edge has initiated coverage on ... Medivation Inc. (NASDAQ: MDVN ), Pharmacyclics Inc. ... MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free ... http://investor-edge.com/register . On Wednesday, October 29, ... the Dow Jones Industrial Average declined 0.18%, to finish ...
(Date:10/30/2014)... SoundConnect , an industry leading ... end users the key to turning this already ... adding voice enablement and hybrid audio conferencing. , ... communication tool that includes presence, instant messaging and ... becomes a comprehensive unified communications solution. Adding the ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success and ... its fleet of high volume High Pressure Processing (HPP) systems. ... return to PackExpo this year, which is where we first ... Jeff Williams, CEO at Avure. “Sales of the new Avure ... meeting the challenges of market demand for higher throughput. We ...
(Date:10/30/2014)... in the development of quantum technologies has been proposed ... published today (28 October) in Nature Communications , ... a new type of flexibly designed microscopic trap for ... and specialised superfast computers, often depend on harnessing the ... these tiny particles are hugely problematic because of the ...
Breaking Biology Technology:Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... DALLAS, October 14, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... Inc., a global leader in the research and development of ... its 2010 UCB Crohn,s and Me Scholarship Program ... 31 winners to receive a scholarship worth up to $10,000 ... The scholarship winners include Crohn,s disease patients, ...
... Kenya and Uganda have laid the groundwork for confined ... varieties of maize genetically modified to survive recurrent droughts ... is life, according to a speech given today by ... at the World Food Prize Symposium. Scientists working ...
Cached Biology Technology:The World Market for Diabetes Treatments Now Available at ReportsandReports 2The World Market for Diabetes Treatments Now Available at ReportsandReports 3The World Market for Diabetes Treatments Now Available at ReportsandReports 4The World Market for Diabetes Treatments Now Available at ReportsandReports 5The World Market for Diabetes Treatments Now Available at ReportsandReports 6The World Market for Diabetes Treatments Now Available at ReportsandReports 7The World Market for Diabetes Treatments Now Available at ReportsandReports 8The World Market for Diabetes Treatments Now Available at ReportsandReports 92010 UCB Crohn's and Me Scholarship Winners Announced 22010 UCB Crohn's and Me Scholarship Winners Announced 32010 UCB Crohn's and Me Scholarship Winners Announced 4Scientists prepare for confined field trials of life-saving drought-tolerant transgenic maize 2Scientists prepare for confined field trials of life-saving drought-tolerant transgenic maize 3
(Date:10/29/2014)... China — BGI Tech and Hebei Agricultural University jointly ... genome. Jujube is the most economically important member of ... difficult to sequence due the high level of heterozygosity ... that a genome in the Rhamnaceae (Buckthorn) family has ... Nature Communications . , Jujube is ...
(Date:10/29/2014)... new study on a large cohort of kidney cancer ... of the disease -- and reveals an apparent link ... cancer, particularly in Romania. , The research, by an ... and Genome Quebec Innovation Centre in Montreal, underscores the ... acid. The compound, found in plants of the Aristolochia ...
(Date:10/28/2014)... to expand the Office of Rare Diseases Research ... Sciences (ORDR-NCATS) collaborative Rare Diseases Clinical Research Network ... 22 consortia will work with 98 patient advocacy ... treatments for patients with rare diseases. The collaborations ... 2014 funding from NIH. , Rett syndrome, MECP2 ...
Breaking Biology News(10 mins):BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3
... sapiens migrating out of Africa began encountering Neanderthals, ... of thousands of years before. Despite their differences, ... produced children with genes from both lineages. Today, the ... remain alive in the genomes of humans with European ...
... a single gene in honey bees separates the queens from ... University and Wayne State University unraveled the gene,s inner workings ... Biology Letters . The gene, which is responsible for leg ... of bees, ability to carry pollen. "This gene is ...
... provider of scientific, technical and medical information products ... journal, Pathogenesis . Pathogenesis ... College of Pathologists a professional membership organization committed ... excellence in the practice of Pathology. The College ...
Cached Biology News:When populations collide 2When populations collide 3When populations collide 4Single gene separates queen from workers 2Elsevier announces the launch of open access journal: Pathogenesis 2
ERalpha (Ser 104/106)...
... Phosphatase, Calf Intestinal (CIAP), catalyzes the hydrolysis ... ribo- and deoxyribonucleoside triphosphates. This enzyme is ... linearized cloning vector DNA by removing phosphate ... be used for the dephosphorylation of 5 ...
Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
Homo sapiens palladin...
Biology Products: